---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-25-000016"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:55:56.212660+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MoonLake Q2 cash $425M; Phase 3 HS readout expected Sept 2025

## Summary
- R&D expenses Q2 $49.8M (up from $36.5M Q1) on trial ramp-up and BLA preparation.
- Cash & equivalents $425.1M; up to $500M non-dilutive debt facility from Hercules Capital.
- Phase 3 VELA (HS) top-line readout on track for ~September 2025; BLA submission planned mid-2026.
- Phase 2 LEDA (PPP) interim readout reported; primary readout expected Q4 2025.
- Cash runway extended into 2028 to support sonelokimab launch in 2027.

## SEC filing metadata
- accession: 0001821586-25-000016
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/0001821586-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/mnlk-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-25-000016
- JSON: https://secwatch.observer/filing/0001821586-25-000016.json
- Plain text: https://secwatch.observer/filing/0001821586-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.